MENLO PARK, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN), will have their samples tested using GRAIL’s novel risk classification test on its Methylation Platform. This assay has been validated for recurrence risk classification in newly diagnosed Stage I lung adenocarcinoma. GRAIL’s Methylation Platform enab ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary disease (COPD), including those who are uninsured and underinsured. Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ As ...

This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery ipopba / iStock via Getty Images Investing in biopharmaceutical stocks comes with more risks than some other types of stocks. Just one unsuccessful clinical trial or a lack of funding can doom biotech startups. But the rewards can be great when investors are on to a winner. Take Novavax Inc. (NASDAQ: NVAX) for example, one of the winners in the race for a COVID-19 vaccine. The Maryland-based vaccine maker was founded in 1987. Its share ...

AstraZeneca PLC (LSE:AZN)’s £780 million takeover of France-based Amolyt Pharma on Thursday failed to tempt much of a reaction from Deutsche Bank analysts. According to the bank, the acquisition “is sufficiently modest to pass under the radar without any visible impact on leverage or profit and losses”. Indeed, net debt and pre-tax earnings came in at US$22.5 billion and US$13.6 billion over the last full year respectively, Deutsche noted. Deutsche reiterated a ‘sell’ rating for AstraZeneca as a result, wit ...

Key TakeawaysAstraZeneca PLC is acquiring Amolyt Pharma for $1.05 billion to strengthen its pipeline for rare diseases, particularly hypoparathyroidism.The deal includes an upfront payment of $800 million with a potential additional payment of $250 million, contingent on meeting regulatory approvals.AstraZeneca said it expects the deal to close by the end of the third quarter of 2024. AstraZeneca PLC (AZN) plans to acquire biotech firm Amolyt Pharma for $1.05 billion in cash, the drugmaker said Thursday, bo ...

AstraZeneca (AZN) announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a private clinical-stage biotech company developing novel treatments for rare endocrine diseases.The impending acquisition is set to strengthen AZN’s late-stage rare disease pipeline and expand its bone metabolism franchise by adding late-stage pipeline candidate, eneboparatide (AZP-3601).Eneboparatide, a PTH receptor 1 agonist with a novel mechanism of action, is Amolyt Pharma’s investigational candidate, ...

AstraZeneca PLC (LSE:AZN) has agreed to buy France-based Amolyt Pharma for $1.05 billion (£780 million) to strengthen the late-stage drug pipeline of its Alexion rare disease arm. Lyon-based Amolyt's lead drug is called eneboparatide (AZP-3601), a treatment for hyperparathyroidism that is currently in Phase III trials. Hypoparathyroidism sufferers cannot generate enough of parathyroid hormone (PTH), resulting in significant dysregulation of calcium and phosphate, which can lead to chronic kidney disease and ...

Astrazeneca (AZN) closed the most recent trading day at $67.58, moving +0.27% from the previous trading session. This change outpaced the S&P 500's 0.19% loss on the day. Elsewhere, the Dow gained 0.1%, while the tech-heavy Nasdaq lost 0.54%.Heading into today, shares of the pharmaceutical had gained 10.44% over the past month, outpacing the Medical sector's gain of 2.91% and the S&P 500's gain of 3.18% in that time.The upcoming earnings release of Astrazeneca will be of great interest to investors. The com ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate, or BGF) on severe cardiopulmonary outcomes, including death*, in people with chronic obstructive pulmonary disease (COPD) who also have elevated cardiopulmonary risk, irrespective of their exacerbation history.1 Also, the first participants have been dosed in ATHLOS, a ...

hapabapa Oncology-focused pharmaceuticals company AstraZeneca PLC (NASDAQ:AZN) has had an underwhelming past year at the stock markets, with just a 3% price rise. However, the limited price change detracts from the fundamental positives of the stock. Here, I look at 5 aspects that set it apart and can provide impetus for price upside in 2024. Price Chart (Source: Seeking Alpha) #1. Improved revenue guidance after an outlook beating 2023 When analyzing any stock, the future financials are, of course, of key ...